About ENB Therapeutics
ENB Therapeutics is a private company based in New York, New York, incorporated in 2018 in Delaware. It has reported $9,602,084 raised in three offerings on Form D since September 2018.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 22, 2023 | Oct 3, 2023 | $225,000of $1.0M target | 3 | $75,000 | Debt, Securities on exerciseRule 506(b) | Form D ↗ |
| Jan 7, 2021 | Jan 11, 2021 | $1,282,500of $2.6M target | 3 | $427K | Debt, Securities on exerciseRule 506(b) | Form D ↗ |
| Sep 7, 2018 | Sep 21, 2018amended Feb 13, 2020 | $8,094,584of $9.0M target | 17 | $476K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, three offerings | $9,602,084 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on ENB Therapeutics's Form D filed Oct 3, 2023.
SJ
Sumayah Jamal
Executive officer and director
BS
Barbara Schilberg
Director
SH
Stuart Hwang
Director
WO
Walter Olesiak
Director
AS
Albert Sokol
Secretary
Earlier filings also listed Fumitaka Mori (director, last listed Jan 2021).